Literature DB >> 2426097

P19, a hormonally regulated phosphoprotein of peptide hormone-producing cells: secretagogue-induced phosphorylation in AtT-20 mouse pituitary tumor cells and in rat and hamster insulinoma cells.

R Pasmantier, A Danoff, N Fleischer, U K Schubart.   

Abstract

P19, a group of 19,000 mol wt cytosolic proteins, with apparent isoelectric points of pI 5.9, pI 5.7, and pI 5.4, respectively, was identified in three peptide hormone-producing cell types: AtT20 mouse pituitary tumor cells, RIN-1122 rat insulinoma cells, and hamster insulinoma cells. Secretagogue-dependent phosphorylation of P19 was analyzed in 32P-labeled cells by two-dimensional electrophoresis and autoradiography. The results were quantitated by computer-assisted densitometry. Cellular levels of cAMP and hormone release were measured in parallel incubations. In addition to stimulating ACTH release, CRF raised the cellular level of cAMP and increased the 32P labeling of all three 19,000 mol wt proteins in AtT20 cells. Other agents known to act through cAMP, which included isoproterenol, forskolin, and 8-bromo-cAMP, mimicked the effect of CRF on both ACTH release and phosphorylation of P19. 12-O-Tetra-decanoylphorbol-13-acetate, a tumor-promoting phorbol ester, also stimulated both ACTH release and phosphorylation of P19. In contrast, although 40 mM K+ promoted ACTH release, it did not affect the phosphorylation of P19. Analogous findings were observed in insulinoma cells. Glucagon stimulated insulin release, increased cellular cAMP and promoted phosphorylation of P19 in RIN 1122 cells. 12-O-Tetradecanoylphorbol-13-acetate also enhanced insulin release and the phosphorylation of P19 in these cells. The results obtained with hamster insulinoma cells closely resembled the observations in RIN-1122 cells. In conclusion, P19, an apparently homologous set of cytosolic proteins, undergoes phosphorylation in three peptide hormone-producing cells in response to two groups of secretagogues, the effect of which is probably mediated, in one case, by cAMP-dependent protein kinase and, in the other, by protein kinase C. The data suggest the possibility that P19 participates in a secretory pathway activated by these two effector systems.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426097     DOI: 10.1210/endo-119-3-1229

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders.

Authors:  Aixiao Liu; Christine Stadelmann; Mario Moscarello; Wolfgang Bruck; Andre' Sobel; Fabrizio G Mastronardi; Patrizia Casaccia-Bonnefil
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

2.  Phosphorylation of stathmin modulates its function as a microtubule depolymerizing factor.

Authors:  F J Moreno; J Avila
Journal:  Mol Cell Biochem       Date:  1998-06       Impact factor: 3.396

3.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Authors:  C M Fife; S M Sagnella; W S Teo; S T Po'uha; F L Byrne; Y Y C Yeap; D C H Ng; T P Davis; J A McCarroll; M Kavallaris
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

4.  Stathmin levels in growth plate chondrocytes are modulated by vitamin D3 metabolites and transforming growth factor-beta1 and are associated with proliferation.

Authors:  T W Hummert; Z Schwartz; V L Sylvia; D D Dean; B D Boyan
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

5.  Interleukin 1 induces early protein phosphorylation and requires only a short exposure for late induced secretion of beta-endorphin in a mouse pituitary cell line.

Authors:  M O Făgărăşan; J F Bishop; M S Rinaudo; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems.

Authors:  Wolfgang Liedtke; Elizabeth E Leman; Robert E W Fyffe; Cedric S Raine; Ulrich K Schubart
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

7.  Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation.

Authors:  V Doye; S Le Gouvello; T Dobransky; H Chneiweiss; L Beretta; A Sobel
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

8.  Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63).

Authors:  P A Curmi; A Maucuer; S Asselin; M Lecourtois; A Chaffotte; J M Schmitter; A Sobel
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

9.  The phosphoprotein stathmin is essential for nerve growth factor-stimulated differentiation.

Authors:  G Di Paolo; V Pellier; M Catsicas; B Antonsson; S Catsicas; G Grenningloh
Journal:  J Cell Biol       Date:  1996-06       Impact factor: 10.539

10.  Overexpression of the stathmin gene in a subset of human breast cancer.

Authors:  I Bièche; S Lachkar; V Becette; C Cifuentes-Diaz; A Sobel; R Lidereau; P A Curmi
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.